Profile data is unavailable for this security.
About the company
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
- Revenue in USD (TTM)101.21m
- Net income in USD-569.00k
- Incorporated2010
- Employees120.00
- LocationCytomX Therapeutics Inc151 Oyster Point Blvd., Suite 400SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 515-3185
- Fax+1 (650) 351-0353
- Websitehttps://cytomx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sangamo Therapeutics Inc | 176.23m | -257.83m | 102.30m | 405.00 | -- | 1.06 | -- | 0.5805 | -1.46 | -1.46 | 1.01 | 0.4653 | 0.4843 | -- | 76.61 | 435,140.80 | -70.85 | -26.09 | -90.72 | -31.04 | -- | -- | -146.30 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| Eliem Therapeutics Inc | 0.00 | -35.12m | 102.64m | 9.00 | -- | 0.9422 | -- | -- | -1.31 | -1.31 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -28.61 | -- | -29.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.64m | 104.11m | 69.00 | -- | 0.855 | -- | -- | -2.13 | -2.13 | 0.00 | 3.24 | 0.00 | -- | -- | 0.00 | -48.43 | -- | -51.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| OptiNose Inc | 70.99m | -35.48m | 104.24m | 132.00 | -- | -- | -- | 1.47 | -0.3162 | -0.3162 | 0.6329 | -0.7705 | 0.5635 | 0.9869 | 2.64 | 537,780.30 | -28.17 | -48.25 | -- | -98.95 | 87.84 | 86.96 | -49.99 | -131.66 | 0.5511 | -1.79 | 2.99 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| Nanopharmaceutics Inc | 1.01m | -549.47k | 104.40m | 50.00 | -- | -- | -- | 103.41 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| aTyr Pharma Inc | 353.00k | -50.39m | 108.71m | 56.00 | -- | 1.12 | -- | 307.95 | -0.9537 | -0.9537 | 0.0066 | 1.43 | 0.0033 | -- | 0.0497 | 6,303.57 | -46.57 | -45.45 | -54.04 | -52.74 | -- | -- | -14,276.77 | -784.19 | -- | -- | 0.0208 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Seres Therapeutics Inc | 126.33m | -113.72m | 110.16m | 233.00 | -- | -- | -- | 0.872 | -0.897 | -0.897 | 0.9829 | -0.3322 | 0.3572 | -- | -- | 542,167.40 | -32.15 | -41.51 | -43.48 | -54.13 | -- | -- | -90.02 | -170.14 | 1.48 | -18.38 | 1.79 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| CytomX Therapeutics Inc | 101.21m | -569.00k | 110.40m | 120.00 | -- | -- | 68.74 | 1.09 | -0.0191 | -0.0191 | 1.37 | -0.7049 | 0.4375 | -- | 5.14 | 843,450.00 | -0.246 | -21.53 | -0.7382 | -32.32 | -- | -- | -0.5622 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| Immunic Inc | 0.00 | -93.61m | 111.51m | 77.00 | -- | 1.94 | -- | -- | -2.11 | -2.11 | 0.00 | 0.6404 | 0.00 | -- | -- | 0.00 | -102.84 | -72.09 | -129.79 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| Bioatla Inc | 0.00 | -123.46m | 113.03m | 65.00 | -- | 1.60 | -- | -- | -2.58 | -2.58 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -71.49 | -48.72 | -84.01 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| Yubo International Biotech Ltd | 604.68k | -1.20m | 113.83m | 18.00 | -- | -- | -- | 188.25 | -0.01 | -0.01 | 0.005 | -0.0154 | 0.3012 | 0.6912 | 9.19 | 33,593.33 | -59.52 | -- | -- | -- | 69.32 | -- | -197.64 | -- | 0.1504 | -3,143.97 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.33m | 113.99m | 22.00 | -- | 1.34 | -- | -- | -0.255 | -0.255 | 0.00 | 0.533 | 0.00 | -- | -- | 0.00 | -36.52 | -30.26 | -38.61 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Emergent Biosolutions Inc | 1.05bn | -760.50m | 114.21m | 1.60k | -- | 0.1753 | -- | 0.1089 | -14.75 | -14.75 | 20.43 | 12.44 | 0.4206 | 2.08 | 5.99 | 655,812.50 | -30.48 | -2.94 | -48.92 | -3.66 | 32.77 | 53.24 | -72.48 | -5.95 | 0.5383 | -1.96 | 0.5699 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| Hongchang International Co Ltd | 2.68m | -378.79k | 115.49m | 8.00 | -- | 2.85 | -- | 43.16 | -0.0009 | -0.0009 | 0.0071 | 0.078 | 0.1065 | -- | 2.78 | -- | -1.51 | -7.98 | -1.60 | -10.94 | 2.59 | 11.47 | -14.16 | -64.88 | 3.74 | -- | 0.1417 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| Rezolute Inc | 0.00 | -56.83m | 115.97m | 51.00 | -- | 1.25 | -- | -- | -1.11 | -1.11 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -45.04 | -58.48 | -47.75 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| Relmada Therapeutics Inc | 0.00 | -98.79m | 116.47m | 20.00 | -- | 1.36 | -- | -- | -3.28 | -3.28 | 0.00 | 2.84 | 0.00 | -- | -- | 0.00 | -78.89 | -- | -87.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
Data as of Apr 24 2024. Currency figures normalised to CytomX Therapeutics Inc's reporting currency: US Dollar USD
39.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Dec 2023 | 6.60m | 9.74% |
| Tang Capital Management LLCas of 31 Dec 2023 | 6.55m | 9.67% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 4.88m | 7.21% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 2.65m | 3.91% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 1.33m | 1.96% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.12m | 1.66% |
| Laurion Capital Management LPas of 31 Dec 2023 | 1.09m | 1.62% |
| Bronte Capital Management Pty Ltd.as of 31 Dec 2023 | 919.91k | 1.36% |
| Millennium Management LLCas of 31 Dec 2023 | 794.05k | 1.17% |
| Jacobs Levy Equity Management, Inc.as of 31 Dec 2023 | 791.42k | 1.17% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
